Last Update 17 May 26

Fair value Decreased 0.66%

SFZN: Lowered Expectations And 2026 Guidance Shift Will Support Future Upside Potential

Narrative Update: Siegfried Holding

Analysts have adjusted their average price target for Siegfried Holding to CHF 103.91, a change of roughly CHF 0.69. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions informed by the recent mix of higher and lower CHF targets from the Street.

Analyst Commentary

Recent Street research shows a split view on Siegfried Holding's valuation, with one firm lifting its price target by CHF 4 and another trimming its target to CHF 96 from CHF 108. This mix of target moves is feeding into the modest change in the overall average price target.

Bullish Takeaways

Bullish analysts see enough support for the investment case to justify raising fair value estimates, even if only by a few francs. This signals confidence in the company’s ability to execute against current expectations.
The higher target suggests some analysts are comfortable with existing P/E and margin assumptions. This indicates they view current valuation levels as reasonable relative to the company’s earnings profile.
The increase in one target, although incremental, reflects a view that recent data points do not undermine the longer term growth story embedded in existing models.

Bearish Takeaways

Bearish analysts are reducing their targets from CHF 108 to CHF 96, which points to concerns that earlier expectations for earnings or margins may have been too optimistic.
The lower target signals caution around how much investors should be willing to pay for the stock on a P/E basis. This suggests less room for valuation expansion from here.
The cut in the target price highlights execution risk, with bearish analysts appearing more focused on the possibility that future results could come in below prior assumptions.
The spread between the higher and lower targets underlines that the market is still working through differing views on growth durability and how that should be reflected in the share price.

What's in the News

Siegfried AG updated its earnings guidance for 2026 and now expects high single digit percent growth in group net sales in local currencies, compared with prior guidance for low single digit percent growth (Key Developments).

Valuation Changes

Fair Value, now at CHF 103.91, is slightly lower than the prior CHF 104.60, indicating a marginal trim to the assessed equity value.
Discount Rate has fallen slightly from 5.09% to 4.80%, which generally supports a somewhat higher present value for future cash flows.
Revenue Growth, reflected in the model at 6.93%, is very close to the prior 7.03%, pointing to only a minimal adjustment in top line expectations.
Net Profit Margin is now set at 14.06%, compared with 13.92% previously, indicating a small uplift in assumed profitability.
Future P/E has eased from 23.03x to 22.53x, signaling a slightly lower valuation multiple applied to forward earnings in current models.

0 views

Key Takeaways

Pharma outsourcing and demand for supply chain resilience position Siegfried for long-term growth, recurring revenues, and stable margins.
Investments in technology and efficient operations, plus strategic acquisitions, support higher-margin growth and improved profitability.
Intense pricing pressure, execution risks in expansion, and sector consolidation threaten Siegfried's margins, growth, and competitiveness amid limited pricing power and long project timelines.

Catalysts

About Siegfried Holding

Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.What are the underlying business or industry changes driving this perspective?

The accelerating trend of pharmaceutical outsourcing, particularly among small and mid-sized pharma companies that lack in-house manufacturing capabilities, positions Siegfried to capture increased volumes and long-term contracts, directly supporting top-line revenue growth and underpinning forward sales visibility.
Industry-wide heightened demand for supply chain resilience and the need for diversified, reliable manufacturing partners after recent disruptions has enabled Siegfried to secure new dual-supply agreements (e.g., for blockbuster drugs), which should increase recurring revenues and provide margin stability through long-duration relationships.
Continuing investments in high-value technology platforms and capacity expansions (e.g., steriles, biologics, GLP-1 capabilities) increase Siegfried's exposure to fast-growing drug categories, supporting higher-margin revenue growth and sustaining overall EBITDA expansion through the mid-term.
Enhanced operational efficiency measures (such as Project FALCON) have already released significant cash flow and reduced inventories, paving the way for improved working capital management and freeing up additional funds for growth investments, thus supporting higher future net income and return on capital.
Active and disciplined M&A strategy, enabled by a strong balance sheet and ample debt capacity, is expected to deliver inorganic revenue and earnings growth, providing incremental synergies and scale benefits that can further expand margins and accelerate EPS growth.

Siegfried Holding Earnings and Revenue Growth

Siegfried Holding Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Siegfried Holding's revenue will grow by 6.9% annually over the next 3 years.
Analysts assume that profit margins will increase from 12.7% today to 14.1% in 3 years time.
Analysts expect earnings to reach CHF 228.2 million (and earnings per share of CHF 5.2) by about May 2029, up from CHF 168.7 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as CHF263.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 22.9x on those 2029 earnings, up from 20.5x today. This future PE is lower than the current PE for the GB Life Sciences industry at 37.0x.
Analysts expect the number of shares outstanding to decline by 0.13% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 4.8%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Increasing pressure on drug pricing, especially from potential U.S. drug price cuts, could adversely affect Siegfried's top-line growth and compress margins over the mid
to long term, as customers seek greater cost reductions from suppliers and CDMOs like Siegfried are forced to compete primarily on price, impacting earnings and profitability.
Siegfried's recent growth has skewed more towards volume rather than pricing power, suggesting limited ability to increase prices in a competitive CDMO market, which, if cost inflation continues or intensifies, could exert sustained pressure on net margins and earnings.
The company faces significant ramp-up periods and long revenue recognition cycles for major CapEx projects (e.g., Minden and Hameln), making near-term revenue and cash flow dependent on successful and timely ramp-up of these facilities; any delays or underutilization could negatively impact both revenue growth and return on invested capital over several years.
Siegfried's ambition to expand its technology offering, particularly into new modalities such as cell and gene therapies, exposes the company to execution risk and potential margin dilution, given its current limited experience in commercial manufacturing and integration of new sites, which could impact profitability if market penetration or operational scaling falls short.
The ongoing trend of industry consolidation and greater automation/digitalization in the CDMO sector favors larger-scale players; mid-sized Siegfried could lose market share or bargaining power to better-capitalized or integrated competitors, leading to slower revenue growth and possibly negative effects on long-term earnings.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF103.91 for Siegfried Holding based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF126.0, and the most bearish reporting a price target of just CHF85.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be CHF1.6 billion, earnings will come to CHF228.2 million, and it would be trading on a PE ratio of 22.9x, assuming you use a discount rate of 4.8%.
Given the current share price of CHF78.9, the analyst price target of CHF103.91 is 24.1% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Siegfried Holding?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Pharmaceutical Outsourcing And Supply Chain Resilience Will Drive Future Expansion